A Personal Word:
Since my transmission into the pharma industry, I have witnessed and experienced firsthand how the role of market access consultants and professionals in the industry has changed because of the increasing discussions about costs leading to stringent HTA procedures. I have observed how departments have increased in size and more functional differentiation within the market access space is being introduced. However, I became intrigued with the notion that the efforts of Pharma companies to address the increasing market access hurdles are not necessarily resulting into access to these medicines for patients equally across Europe.
Being a person that is naturally curious and investigative, with a mindset to challenge the status quo, I realized that in a highly regulated market such as the healthcare market, you cannot ignore the interests of other healthcare system actors. This is not only true for biopharma companies, but also for Biotech and MedTech. To be able to address the needs of payers, doctors, patients and other stakeholders, there is still much to gain from well thought and fully team-owned market access strategies that are well integrated into the commercial strategy of the companies. It begins with an early start.